Saturday 17 October 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.
25.07
0.68
−2.64%
Follow ZYME
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
51.39 | 23.01 | 18.74 | 9.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(59.72) | (40.90) | (193.53) | (41.20) | |
P/B ratio |
23.74 | 11.43 | 7.39 | 4.04 | |
Price to Tangible BV |
28.33 | 12.43 | 7.78 | 4.22 | |
EV/Sales |
44.11 | 18.52 | 16.58 | 7.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(13.72) | (19.99) | (53.23) | (16.57) | |
EV/FCF |
(13.49) | (19.33) | (49.69) | (16.08) | |
Quick Ratio |
5.86 | 10.36 | 5.52 | 6.69 | |
Current Ratio |
6.32 | 10.82 | 5.88 | 6.94 | |
Net Debt/EBITDA |
6.74 | 8.24 | 5.42 | 12.90 | |
Debt/Assets |
0.00% | 0.06% | 0.08% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.18 | 0.26 | 0.30 | |
Operating CF/Net income |
0.71 | 1.04 | 0.25 | 1.60 | |
Capex/Depreciation |
0.00 | (0.08) | (0.36) | (0.16) | |
Interest Coverage |
(6.40) | (22.81) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
421.24% | 625.79% | 613.60% | 51.23% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.04 | 0.03 | |
Share Based Compensation of Revenue |
246.93% | 288.00% | 351.89% | 25.03% | |
Graham Net Nets |
(0.01) | 0.04 | 0.09 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.73%) | (5.47%) | (4.10%) | (4.92%) | |
Free Cash Flow Yield |
(6.36%) | (4.16%) | (1.78%) | (5.12%) | |
Revenue per Share |
0.06 | 0.03 | 0.03 | 0.36 | |
Operating CF per Share |
(0.44) | (0.61) | (0.14) | (0.41) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.44) | (0.62) | (0.15) | (0.42) | |
Cash per Share |
3.71 | 4.88 | 3.03 | 3.33 | |
Shareholders Equity per Share |
1.10 | 2.19 | 3.56 | 4.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.10 | 2.19 | 3.56 | 4.22 | |
Free Cash Flow |
(31.95) | (45.93) | (10.98) | (31.82) | |
Working Capital |
251.15 | 350.03 | 206.45 | 249.67 | |
Capital Expenditures |
0.00 | (0.22) | (0.72) | (0.41) | |
Net Current Asset Value |
(18.21) | 71.05 | 170.74 | 214.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.09 | 0.29 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.28 | 14.63 | 30.23 | 26.53 | |
Average Payables |
29.23 | 34.22 | 48.09 | 43.07 | |
Average Assets |
402.67 | 451.87 | 404.81 | 442.21 | |
Average Common Equity |
207.44 | 244.28 | 303.63 | 343.52 |
Columns are period end dates